AU2022262659A1 - Novel ergolines and methods of treating mood disorders - Google Patents

Novel ergolines and methods of treating mood disorders Download PDF

Info

Publication number
AU2022262659A1
AU2022262659A1 AU2022262659A AU2022262659A AU2022262659A1 AU 2022262659 A1 AU2022262659 A1 AU 2022262659A1 AU 2022262659 A AU2022262659 A AU 2022262659A AU 2022262659 A AU2022262659 A AU 2022262659A AU 2022262659 A1 AU2022262659 A1 AU 2022262659A1
Authority
AU
Australia
Prior art keywords
disorder
alkyl
compound
group
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022262659A
Other languages
English (en)
Inventor
Andrew Carry KRUEGEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilgamesh Pharmaceuticals Inc
Original Assignee
Gilgamesh Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilgamesh Pharmaceuticals Inc filed Critical Gilgamesh Pharmaceuticals Inc
Publication of AU2022262659A1 publication Critical patent/AU2022262659A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D457/00Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06Lysergic acid amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/48Ergoline derivatives, e.g. lysergic acid, ergotamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D457/00Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06Lysergic acid amides
    • C07D457/08Lysergic acid amides in which the amide nitrogen is a member of a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2022262659A 2021-04-23 2022-04-25 Novel ergolines and methods of treating mood disorders Pending AU2022262659A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163179053P 2021-04-23 2021-04-23
US63/179,053 2021-04-23
US202263308376P 2022-02-09 2022-02-09
US63/308,376 2022-02-09
PCT/US2022/026186 WO2022226408A1 (en) 2021-04-23 2022-04-25 Novel ergolines and methods of treating mood disorders

Publications (1)

Publication Number Publication Date
AU2022262659A1 true AU2022262659A1 (en) 2023-10-19

Family

ID=81648213

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022262659A Pending AU2022262659A1 (en) 2021-04-23 2022-04-25 Novel ergolines and methods of treating mood disorders

Country Status (10)

Country Link
US (1) US20240368151A1 (https=)
EP (1) EP4326718A1 (https=)
JP (1) JP2024516174A (https=)
KR (1) KR20240019091A (https=)
AU (1) AU2022262659A1 (https=)
BR (1) BR112023021970A2 (https=)
CA (1) CA3223210A1 (https=)
IL (1) IL307880A (https=)
MX (1) MX2023012447A (https=)
WO (1) WO2022226408A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230116703A1 (en) * 2021-04-23 2023-04-13 Gilgamesh Pharmaceuticals, Inc. Novel ergolines and methods of treating mood disorders
CN117355302A (zh) 2021-04-30 2024-01-05 思维医学股份有限公司 Lsd盐晶体形式
JP2024529727A (ja) 2021-08-19 2024-08-08 マインド メディシン, インコーポレイテッド 治療適用のためのd-リゼルグ酸ジエチルアミドの凍結乾燥された口腔内崩壊錠製剤
JP2025525375A (ja) * 2022-06-20 2025-08-05 マインド メディシン, インコーポレイテッド 修飾lsd様作用を有するリゼルグ酸誘導体
EP4630418B1 (en) * 2022-12-31 2026-03-18 Ceruvia Lifesciences LLC Salts of 2-bromolysergic acid diethylamide
EP4704846A2 (en) * 2023-05-04 2026-03-11 Gilgamesh Pharmaceuticals, Inc. Novel ergolines and methods of treating mood disorders
WO2025194238A1 (en) * 2024-03-22 2025-09-25 Blife Therapeutics Inc. 2-bromo-lsd salts and polymorphs
WO2025235800A1 (en) 2024-05-08 2025-11-13 Cy Biopharma Ag Ergoline derivatives and uses thereof
WO2025235784A2 (en) * 2024-05-08 2025-11-13 Cy Biopharma Ag Ergoline derivatives and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2438259A (en) * 1948-03-23 D-lysergic acid diethyl amide
CN1087725C (zh) * 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
EP4219498A1 (en) * 2019-03-07 2023-08-02 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations
US20230295106A1 (en) * 2019-10-14 2023-09-21 The Regents Of The University Of California Ergoline-like compounds for promoting neural plasticity
EP4178956A2 (en) * 2020-07-07 2023-05-17 COMPASS Pathfinder Limited Improved method for the production of lysergic acid diethylamide (lsd) and novel derivatives thereof

Also Published As

Publication number Publication date
IL307880A (en) 2023-12-01
US20240368151A1 (en) 2024-11-07
EP4326718A1 (en) 2024-02-28
WO2022226408A1 (en) 2022-10-27
CA3223210A1 (en) 2022-12-27
JP2024516174A (ja) 2024-04-12
KR20240019091A (ko) 2024-02-14
BR112023021970A2 (pt) 2023-12-26
MX2023012447A (es) 2023-10-31

Similar Documents

Publication Publication Date Title
AU2022262659A1 (en) Novel ergolines and methods of treating mood disorders
US20230116703A1 (en) Novel ergolines and methods of treating mood disorders
US20030212094A1 (en) Novel cyclic amide derivatives
CN109496213B (zh) 螺环化合物及其制备和使用方法
US20240166618A1 (en) Phenalkylamines and methods of making and using the same
JP7237010B2 (ja) Hdac6選択的阻害剤およびその製造方法と使用
EP4704846A2 (en) Novel ergolines and methods of treating mood disorders
TWI695831B (zh) Crth2拮抗劑化合物及其用途
EP2445877B1 (en) Bicyclic compounds and methods of making and using same
JP6236439B2 (ja) ヘテロアリール化合物及びその使用方法
ES2782088T3 (es) Compuestos novedosos
US10017507B2 (en) Diaza-benzofluoranthrene compounds
CN105985333A (zh) 二氮杂-苯并荧蒽类化合物
JP2010502760A (ja) うつ病の治療用の3−アザビシクロ[4.1.0]ヘプタン誘導体
MX2007016217A (es) Compuestos de alfa-(aril- o heteroaril-metil)-beta-piperidinopropa namida como antagonista del receptor orl1.
CN120787225A (zh) 新型麦角林类和治疗心境障碍的方法
CN117677618A (zh) 新颖的麦角灵类和治疗心境障碍的方法
TWI858711B (zh) R拮抗劑及其用途
TWI854832B (zh) 苯烷胺及其製造與使用方法
WO2025059373A1 (en) Novel phenalkylamines and their use in the treatment of psychiatric disorders
WO2026076223A1 (en) Therapeutic compounds and methods of use thereof
HK40004417A (en) Spirocycle compounds and methods of making and using same
HK40009413B (en) Hdac6 selective inhibitors, preparation method therefor, and application thereof
WO2014157437A1 (ja) プロペラン誘導体